Efficacy and Safety of Tirofiban for Patients With BAD (BRANT)
Status:
Recruiting
Trial end date:
2025-10-31
Target enrollment:
Participant gender:
Summary
Branch atheromatous disease (BAD)-related stroke, characterized by subcortical single
infarcts without severe stenosis of the large artery, but with a clear atherosclerotic
mechanism, is now regarded as a separate stroke type. BAD is associated with early
neurological deterioration and poor prognosis, but is lack of effective therapy. The goal of
this randomized controlled trial is to test the efficacy and safety of intravenous tirofiban
in patients with acute ischemic stroke caused by branch atheromatous disease. The main
question it aims to answer is: Compared with standard antiplatelet therapy based on current
stroke guideline, whether tirofiban used in acute phase of BAD could improve the proportion
of excellent functional outcome (modified Rankin Scale: 0-1) at 90 days. Researcher will also
compare the rate of major bleeding between treatment and control groups.